The goal of this dissertation was to investigate the role of μ-opioid receptors in the mechanism of ethanol-stimulated dopamine release in the nucleus accumbens shell (NAcS) of rats. The underlying hypothesis is that blockade of the μ-opioid receptors leads to an attenuation of ethanol-stimulated mesolimbic dopamine release. We prepared ethanol-naïve male Long Evans rats (n = 95) for intravenous (i.v.) drug administration and in vivo microdialysis (in awake, freely moving animals), and analyzed our samples using HPLC and GC for dopamine and ethanol detection, respectively. In one set of experiments, we looked at the effects of naltrexone, a non-selective opioid antagonist, on ethanol-stimulated mesolimbic dopamine release. First of all, we checked to see if naltrexone affected basal dopamine levels in the NAcS. Thereafter, we looked for a dose of naltrexone (i.v.) that was effective in suppressing the release of dopamine in the NAcS evoked by morphine (1 mg/kg, i.v.). Subsequently, we checked to see if doses of naltrexone that inhibited morphine-evoked dopamine were also effective in attenuating dopamine release due to ethanol (1g/kg, 10% w/v, i.v.). To do this, we pretreated rats with naltrexone doses, followed 20 min later by morphine, ethanol or saline (all drugs were administered i.v.). In another set of experiments, we looked at the effect of β-funaltrexamine, a selective μ-opioid antagonist, on ethanol-stimulated dopamine release in the NAcS. Similarly to the previous set of experiments, we looked for a dose of β-funaltrexamine (s.c.) that was effective in suppressing the release of dopamine the NAcS evoked by morphine (1 mg/kg, i.v.), and checked to see if this dose of β-funaltrexamine was also effective in attenuating ethanol-stimulated dopamine release in the NAcS. For the β-funaltrexamine experiments, rats were pretreated with β-funaltrexamine (s.c.) 20-25 h before i.v. infusions of saline, morphine and ethanol.
Morphine increased dopamine release in the NAcS. Naltrexone and β-funaltrexamine significantly attenuated morphine-evoked dopamine release. Also, ethanol increased dopamine release in the NAcS. Naltrexone and β-funaltrexamine, at doses effective in attenuating morphine-evoked dopamine release, suppressed the prolongation, but not the initiation of dopamine release in the NAcS due to ethanol. Naltrexone and β-funaltrexamine did not affect the peak concentration and clearance of ethanol in the brain. The conclusion of this study is that the μ-opioid receptors are involved in a delayed component of ethanol-stimulated dopamine release in the NAcS in ethanol-naïve rats. This is the first study to show that the ethanol-stimulated dopamine response consists of a delayed μ-opioid mechanism.
|Advisor:||Gonzales, Rueben A.|
|Commitee:||Duvauchelle, Christine L., Erickson, Carlton K., Morikawa, Hitoshi, Morrisett, Richard A.|
|School:||The University of Texas at Austin|
|School Location:||United States -- Texas|
|Source:||DAI-B 70/09, Dissertation Abstracts International|
|Subjects:||Neurosciences, Pharmacology, Pharmacy sciences|
|Keywords:||Beta-funaltrexamine, Dopamine release, Ethanol, Mesolimbic dopamine, Morphine, Naltrexone, Nucleus accumbens|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be